Under a tenth of individuals who could benefit from weight-loss injections like Wegovy can access them, warns the WHO as it releases its inaugural advice on the medications.
Considering over a billion individuals worldwide currently classified as obese, it is advocating for broader and more equitable availability to this class of drugs.
Per forecasts, more than two billion are projected to be obese by 2030 if no action is taken.
"Our new guidelines affirms that obesity is a lifelong illness that can be addressed with holistic and ongoing care," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are major obstacles to universal availability to the treatments that can assist patients in reducing substantial weight, explains the body.
Skinny Jab Scarcity
Even in the present most optimistic outlook, the manufacturing of GLP-1 therapies might only reach approximately 100 million people – less than 10% of those who need them, per the health organization.
The recommendation urges countries and companies to widen availability, by strategies such as licensing agreements.
The intellectual property rights on a key compound – the main ingredient of Novo Nordisk's Wegovy – is set to lapse in several nations in 2026.
The Way Weight-Loss Drugs Work
These medications mimick a body's own hormone to delay gastric emptying, reduce hunger and boost feelings of fullness so users eat less.
Individuals usually see weight reduction after several weeks of commencing the regular doses.
Evidence indicates patients may put most of the weight back on within a year of stopping the medication, as their usual food cravings come back.
Being overweight or obese elevates your likelihood for developing diseases, like type 2 diabetes, cardiovascular issues, stroke, and certain cancers.
Obesity impacts people in countries worldwide and was associated with 3.7 million deaths worldwide in 2024, per the WHO.
